3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Breast
1
Conditions
Breast Neoplasms
47
Breast Neoplasms, Male
5
Neoplasms
4
Neoplasm Metastasis
4
Carcinoma, Ovarian Epithelial
2
Sarcoma
1
Recurrence
1
Pancreatic Neoplasms
1
Pain
1
Ovarian Neoplasms
1
Lung Neoplasms
1
Liver Neoplasms
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Fallopian Tube Neoplasms
1
Colonic Neoplasms
1
Carcinoma
1
Breast Cancer Organoids
1
Bilateral Breast Carcinoma
1
Interventions
pembrolizumab
6
Paclitaxel
3
Docetaxel
3
Cyclophosphamide
3
eribulin
2
Oncolytic Virotherapy
2
tislelizumab
1
tirbanibulin
1
spartalizumab
1
poly ICLC
1
pertuzumab
1
pemigatinib
1
pegfilgrastim
1
obinutuzumab
1
ixabepilone
1
fludarabine phosphate
1
fludarabine
1
etirinotecan pegol
1
efineptakin alfa
1
durvalumab
1
atezolizumab
1
aldesleukin
1
advexin
1
Yoga
1
Vinorelbine
1
Tomography, X-Ray Computed
1
Surveys and Questionnaires
1
Ritonavir
1
Radiotherapy
1
Radiation
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma
×
ixabepilone
×
Breast
×
Clear all
NCT02915744
2023-04-14
ATTAIN
Nektar Therapeutics
Phase 3
Completed
178 enrolled
37 charts